{"id":"NCT03619213","sponsor":"AstraZeneca","briefTitle":"Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.","officialTitle":"An International, Double-blind, Randomised, Placebo-Controlled Phase III Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-08-27","primaryCompletion":"2022-03-27","completion":"2022-03-27","firstPosted":"2018-08-07","resultsPosted":"2023-07-11","lastUpdate":"2023-07-11"},"enrollment":6263,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Heart Failure With Preserved Ejection Fraction"],"interventions":[{"type":"DRUG","name":"Dapagliflozin","otherNames":["Forxiga TM","Farxiga TM"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Dapagliflozin","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is an international, multicentre, parallel-group, event-driven, randomised, double-blind, placebo-controlled study in HFpEF patients, evaluating the effect of dapagliflozin 10 mg versus placebo, given once daily in addition to background regional standard of care therapy, including treatments to control co-morbidities, in reducing the composite of CV death or heart failure events.","primaryOutcome":{"measure":"Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure.","timeFrame":"Up to 42.1 months","effectByArm":[{"arm":"Dapa 10 mg","deltaMin":512,"sd":null},{"arm":"Placebo","deltaMin":610,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0008"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":348,"countries":["United States","Argentina","Belgium","Brazil","Bulgaria","Canada","China","Czechia","Hungary","Japan","Mexico","Netherlands","Peru","Poland","Romania","Russia","Saudi Arabia","Spain","Taiwan","Vietnam"]},"refs":{"pmids":["40834567","40488583","40047763","39909641","39745404","38320525","38265835","37952176","37886880","37830208","37771274","37767674","37634707","37634087","37632455","37294244","37226448","37220822","37220172","37220093","37212168","37211977","37210608","37208998","37099283","36889870","36881399","36876483","36811901","36599553","36526515","36522606","36372069","36326604","36190011","36189985","36114137","36100197","36041912","36041669","36041668","36029467","36029465","36027570","35241246","34693515","31081589"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D169CC00001&amp;attachmentIdentifier=219ed7c1-2b33-4f6b-be14-6261816c74e8&amp;fileName=D169CC00001_DELIVER_CSP_12Nov2020_version_4.0_Redacted2.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D169CC00001&amp;attachmentIdentifier=8cd4f2a7-521d-4001-9dfc-351e1b077a4d&amp;fileName=D169CC00001_-___Statistical_Analysis_Plan_v5.0_Redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D169CC00001&amp;attachmentIdentifier=6d2e647c-a9ac-445e-b0b8-91a252dcd8a4&amp;fileName=D169CC00001-CSR-Synopsis_Redacted.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":1454,"n":3126},"commonTop":["Cardiac failure","Urinary tract infection","Hypertension","Atrial fibrillation","Hypotension"]}}